INVION LIMITED — AGM Information 2012

Oct 4, 2012

ASX / MEDIA ANNOUNCEMENT

==> picture [161 x 76] intentionally omitted <==

5 October 2012

ANNUAL GENERAL MEETING AND ANNUAL REVIEW

Australian drug development company Invion Limited (ASX:IVX) is pleased to confirm that its Annual General Meeting of Shareholders will be held at 10.30am, Thursday, 8 November 2012 at the offices of McCullough Robertson Lawyers, Level 11, 66 Eagle Street, Brisbane.

Shareholders as of the record date of 6 November 2012 are entitled to attend and vote at the meeting.

The Notice of Annual General Meeting and Explanatory Memorandum accompanying this announcement has today been mailed to Shareholders.

Invion Limited’s inaugural Annual Review is also released today.

About Invion Limited

Invion Limited is a clinical-stage drug development company that targets chronic inflammation. Focussed on the development of treatments for major market opportunities in inflammatory diseases including asthma, chronic bronchitis and lupus, Invion has two phase II proprietary therapeutic candidates: INV102 – a repurposed beta adrenergic inverse agonist; and Cpn10 – a modified natural immunomodulator. INV102, also known as nadolol, has been used in more than 8 million people for the treatment of high blood pressure, migraine and chest pain. Invion is now targeting INV102 for new indications. To date, two phase II clinical trials of INV102 have been completed which have demonstrated acceptable safety as well as dose-related activity showing a reduction of airway hyper-responsiveness. Two further phase II trials are due to commence in 2H 2012. The larger of these trials, a phase II $4.4 million study in asthma patients, is being funded by the US National Institutes of Health (NIH). Cpn10 is a potential new anti-inflammatory biologic therapeutic. In clinical trials carried out to date, Cpn10 has demonstrated signs of biological activity, including a reduction in disease-relevant pro-inflammatory cytokines. Invion is progressing regulatory preparations to investigate Cpn10 as a treatment for systemic lupus erythematosus (SLE or lupus). Invion’s pre-Investigational New Drug (pre-IND) meeting with the US Food and Drug Administration (FDA) is scheduled for 14 December 2012.

FOR MORE INFORMATION CONTACT:

Corporate

Corporate Investor Relations Media Dr William Garner Rebecca Wilson Tom Donovan Managing Director and CEO Buchan Consulting Buchan Consulting Invion Limited 03 9866 4722 (03) 9866 4722 investor@invion.com.au rwilson@buchanwe.com.au tdonovan@buchanwe.com.au

==> picture [43 x 24] intentionally omitted <==

Invion Limited ABN 76 094 730 417

Unit 2, 120 Bluestone Circuit, Seventeen Mile Rocks, QLD 4073 P +61 7 3295 0500 F +61 7 3295 0599 www.invion.com.au